NRCS
NOTICE OF REGISTRATION CONFIRMATION EMAILED
05/23/2023
Back to search
Official data from USPTO
NUCLEAR-DELIVERED ANTIBODY-DRUG CONJUGATES
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
NUCLEAR-DELIVERED ANTIBODY-DRUG CONJUGATES
ST13
US500000097296549Class
42
Filing
97296549
Registration
7064074
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
25
Latest update
05/23/2023
Trademark type
Word
Nice classes
42
Filing date
03/04/2022
Registration date
05/23/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
05/23/2023
Last transaction
05/23/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Supplemental Register
Filing basis
Intent to use
First use anywhere
01/10/2020
First use in commerce
01/10/2020
Drawing code
4
Owner type
03
Owner location
Cambridge, MA, US
Examiner
BAL,KAMAL S
Law office
N70
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Angiex, Inc.
Representatives
Chelsea E. Carbone WILSON SONSINI GOODRICH & ROSATI
Technical classification
Nice Classes
Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Scientific research and development in the fields of cancerimmunological-inflammatory conditionstissue repaireye diseasescardiovascular diseasebiologylaboratory testingbiotechnologybiochemistrymedicine; research and product development services for others in the fields of cancerimmunological-inflammatory conditionstissue repaireye diseasescardiovascular diseasebiologylaboratory testingbiotechnologybiochemistrymedicine; Medical and scientific research in the fields of cancerimmunological-inflammatory conditionstissue repaireye diseasescardiovascular disease detection; Providing information on the subject of scientific research in the fields of cancerimmunological-inflammatory conditionstissue repaireye diseasescardiovascular diseasebiologylaboratory testingbiotechnologybiochemistrymedicine
Publications
History of USPTO decisions and trademark events.
25 publications found
R.SR
REGISTERED-SUPPLEMENTAL REGISTER
05/23/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
04/21/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/21/2023
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
04/21/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
04/21/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
04/21/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
04/21/2023
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
04/17/2023
ALIE
ASSIGNED TO LIE
04/12/2023
AAUA
NOTICE OF ACCEPTANCE OF AMENDMENT TO ALLEGE USE E-MAILED
03/31/2023
CNTA
APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER
03/30/2023
IUAA
USE AMENDMENT ACCEPTED
03/30/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/07/2023
AUPC
AMENDMENT TO USE PROCESSING COMPLETE
03/07/2023
IUAF
USE AMENDMENT FILED
03/07/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/06/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/06/2023
EAAU
TEAS AMENDMENT OF USE RECEIVED
03/06/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
12/22/2022
GNRT
NON-FINAL ACTION E-MAILED
12/22/2022
CNRT
NON-FINAL ACTION WRITTEN
12/22/2022
DOCK
ASSIGNED TO EXAMINER
12/15/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/09/2022
NWAP
NEW APPLICATION ENTERED
03/08/2022
Continuous trademark protection
Get notified about every new filing that threatens NUCLEAR-DELIVERED ANTIBODY-DRUG CONJUGATES or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.